

=> fil hcaplu

FILE 'HCAPLUS' ENTERED AT 16:40:42 ON 20 AUG 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 20 Aug 2001 VOL 135 ISS 9

FILE LAST UPDATED: 19 Aug 2001 (20010819/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

HCAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

=> d stat que

L1 3 SEA FILE=REGISTRY SYIVLCIE/SQSP NOT NSFMTSFSK/SQSP
L2 4 SEA FILE=HCAPLUS L1

=> d ibib abs hitrn l2 1-4

L2 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:814324 HCAPLUS

DOCUMENT NUMBER: 134:505

TITLE: Antiangiogenic endostatin peptides, endostatin variants and methods of use

INVENTOR(S): Vuori, Kristiina

PATENT ASSIGNEE(S): The Burnham Institute, USA

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067771	A1	20001116	WO 2000-US12063	20000502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB,				

M. Smith 308-3278

GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-132907 P 19990506
US 1999-353333 A2 19990714

AB The invention provides an endostatin peptide having at least 4-7
endostatin amino acid residues contg. substantially the amino acid
sequence of RLQD, RAD, DGK/R, or a functional equiv. thereof. The
invention also provides an endostatin variant contg. the amino acid
sequence RGD, or a functional fragment thereof. Methods of inhibiting
angiogenesis are also provided.

IT 307924-80-7

RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological
study); OCCU (Occurrence)
(antiangiogenic endostatin peptides, endostatin variants and methods of
use)

REFERENCE COUNT: 7

REFERENCE(S): (1) Brooks; US 5753230 A 1998 HCAPLUS
(2) Koivunen, E; Journal of Biological Chemistry 1993,
V268(27), P20205 HCAPLUS
(3) La Jolla Cancer Research Foundation; WO 9514714 A1
1995 HCAPLUS
(4) Nutt; US 5061693 A 1991 HCAPLUS
(5) Oh, S; Proc Natl Acad Sci USA 1994, V91, P4229
HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:434233 HCAPLUS

DOCUMENT NUMBER: 133:79332

TITLE: Carrier-DNA complexes containing DNA encoding
anti-angiogenic peptides and their use in gene therapy

INVENTOR(S): Mixson, A. James

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 30 pp., Cont.-in-part of U.S. 5,815,216.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6080728	A	20000627	US 1997-985526	19971205
EP 819758	A2	19980121	EP 1997-112154	19970716
EP 819758	A3	19980204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 921193	A1	19990609	EP 1998-100135	19980107

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 11187886 A2 19990713 JP 1998-201996 19980716
PRIORITY APPLN. INFO.: US 1996-680845 A2 19960716
EP 1997-112154 A 19970716
US 1997-985526 A 19971205

AB Carrier complexes comprising DNA encoding an anti-angiogenic gene or peptide and optionally a further DNA encoding a tumor suppressor protein are described. When administered to a subject bearing a tumor, the complexes can inhibit growth of the tumor.

IT 226938-38-1, Endostatin (human fragment)

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; carrier-DNA complexes contg. DNA encoding anti-angiogenic peptides and their use in gene therapy)

REFERENCE COUNT: 40

REFERENCE(S): (1) Anon; EP 0443404 A1 1991 HCAPLUS
(2) Anon; WO 9202240 1992 HCAPLUS
(3) Anon; WO 9316716 1993 HCAPLUS
(4) Anon; WO 9316718 1993 HCAPLUS
(5) Anon; WO 9529242 1995 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:62891 HCAPLUS

DOCUMENT NUMBER: 132:103744

TITLE: Cloning of cDNA for human endostatin and use for inhibition of angiogenesis

INVENTOR(S): Xu, Genxing; Ren, Mindong; Xu, Lin

PATENT ASSIGNEE(S): Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 6 pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1177005	A	19980325	CN 1997-107112	19970910
CN 1060521	B	20010110		

AB Described is a method of cloning the cDNA for human liver endostatin by PCR using a pair of primers derived from the cDNA encoding human collagen type XVIII (1503-2055 cDNA fragment). Endostatin is useful for the treatment of tumors by inhibiting angiogenesis.

IT 255811-03-1

RL: PRP (Properties)

(unclaimed sequence; cloning of cDNA for human endostatin and use for inhibition of angiogenesis)

L2 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:375339 HCAPLUS

DOCUMENT NUMBER: 131:28626

TITLE: Delivery of anti-angiogenic genes to a tumor in vivo

INVENTOR(S): and their use in gene therapy
 MIXSON, Archibald James
 PATENT ASSIGNEE(S): USA
 SOURCE: Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 921193	A1	19990609	EP 1998-100135	19980107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6080728	A	20000627	US 1997-985526	19971205
PRIORITY APPLN. INFO.:				
			US 1997-985526	A 19971205
			US 1996-680845	A2 19960716
			EP 1997-112154	A 19970716

AB The invention relates to the delivery of anti-angiogenic genes or DNA encoding anti-angiogenic peptides to a tumor in vivo, preferably by injection, and expression of the DNA in order to inhibit tumoral growth. Provided are carrier:DNA complexes which comprise cationic polymers or cationic liposomes and DNA encoding at least one anti-angiogenic protein/peptide, optionally together with further DNA encoding a tumor suppressor protein, esp. p53. When administered to a subject bearing a tumor, the complexes can inhibit growth of the tumor.

IT **226938-38-1P**, Endostatin (human fragment)
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; delivery of anti-angiogenic genes to a tumor in vivo and their use in gene therapy)

REFERENCE COUNT: 6

REFERENCE(S):

- (1) Chiron Viagene Inc; WO 9621416 A 1996 HCAPLUS
- (2) Lesoon-Wood, L; Human Gene Therapy 1995, V6(4), P395 HCAPLUS
- (3) Mixson, A; EP 0819758 A 1998 HCAPLUS
- (4) The Children's Medical Center Corporation; WO 9529242 A 1995 HCAPLUS
- (5) Weinstat-Saslow, D; Cancer Research 1994, V54, P6504 HCAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:41:24 ON 20 AUG 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 AUG 2001 HIGHEST RN 351975-45-6

DICTIONARY FILE UPDATES: 19 AUG 2001 HIGHEST RN 351975-45-6

M. Smith 308-3278

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d rn cn lc nte sql kwic can tot 11

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2001 ACS
RN 307924-80-7 REGISTRY
CN L-Methionine, L-.alpha.-glutamyl-L-seryl-L-tyrosyl-L-cysteinyl-L-.alpha.-glutamyl-L-threonyl-L-tryptophyl-L-arginyl-L-threonyl-L-.alpha.-glutamyl-L-threonyl-L-threonylglycyl-L-alanyl-L-threonylglycyl-L-glutaminy-L-alanyl-L-seryl-L-seryl-L-leucyl-L-leucyl-L-serylglycyl-L-arginyl-L-leucyl-L-leucyl-L-.alpha.-glutamyl-L-glutaminy-L-lysyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-histidyl-L-asparaginy-L-seryl-L-tyrosyl-L-isoleucyl-L-valyl-L-leucyl-L-cysteinyl-L-isoleucyl-L-.alpha.-glutamyl-L-asparaginy-L-seryl-L-phenylalanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 11: PN: WO0067771 SEQID: 21 claimed protein
LC STN Files: CA, CAPLUS, TOXLIT
SQL 48

SEQ 1 ESYCETWRTE TTGATGQASS LLSGRLLLEQK AASCHNSYIV LCIENSEFM
=====

HITS AT: 37-44

REFERENCE 1: 134:505

L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2001 ACS
RN 255811-03-1 REGISTRY
CN 4: PN: CN1177005 PAGE: 4 unclaimed sequence (9CI) (CA INDEX NAME)
LC STN Files: CA, CAPLUS, TOXLIT
NTE

type	location	description
uncommon	Aaa-181	-

SQL 181

SEQ 151 SLLSGRLLLEQ KAASCHNSYI VLCIENSFMT X
====

HITS AT: 168-175

REFERENCE 1: 132:103744

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2001 ACS
RN 226938-38-1 REGISTRY
CN Endostatin (human fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 31: PN: US6080728 SEQID: 36 claimed protein

M. Smith 308-3278

CN Endostatin (synthetic 185-amino acid fragment)
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL
SQL 185

SEQ 151 SSLLSGRLLE QRAASCHDSY IVLCIENSFM TSFSR
== =====

HITS AT: 169-176

REFERENCE 1: 133:79332

REFERENCE 2: 131:28626